WEKO3
アイテム
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
https://repo.qst.go.jp/records/44880
https://repo.qst.go.jp/records/44880f612b552-35e4-4d46-85ee-83d1d236c0e3
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2007-06-15 | |||||
| タイトル | ||||||
| タイトル | Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Nakamura, Kazutaka
× Nakamura, Kazutaka× Yamaguti, Taketo× Ishihara, Takeshi× Kobayashi, Akitoshi× Tadenuma, Hiroshi× Sudo, Kentaro× Katou, Hirotoshi× Saisho, Hiromitsu× 山口 武人× 加藤 博敏× 税所 宏光 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study. S-1 was given orally (30 mg m(-2)) b.i.d. for 14 consecutive days and gemcitabine (1000 mg m(-2)) was given on days 8 and 15. The cycle was repeated every 21 days. We enrolled 33 MPC patients. The median number of cycles was eight (range 1-20). Grade 3-4 toxicities were leucopenia (33%), neutropenia (55%), anaemia (9%), thrombocytopenia (15%), anorexia (6%), fever (9%), and interstitial pneumonia (6%). Objective responses were obtained in 16 patients (one complete response and 15 partial responses; response rate, 48%; 95% confidence interval (CI), 33-65). Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate. | |||||
| 書誌情報 |
British Journal of Cancer 巻 94, 号 11, p. 1575-1579, 発行日 2006-06 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0007-0920 | |||||
